BPC-157

RESEARCH CONTEXT

BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice, first characterized by Sikiric et al. in 1993.

It is one of the most extensively studied peptides in the current preclinical literature, with a 2025 systematic review identifying 544 published articles spanning musculoskeletal, gastrointestinal, and neurological research domains. PubMed indexed over 180 BPC-157-related publications in 2025 alone — a fourfold increase over 2020.

Research interest centers on several mechanisms investigated in preclinical models: VEGFR2-mediated angiogenesis (Hsieh et al., 2017), nitric oxide system modulation (Sikiric et al., 2014), growth hormone receptor interaction, and inflammatory cytokine regulation.

Its unusual stability in gastric juice — unlike most peptides — makes it a distinctive model compound for researchers studying peptide stability and bioavailability across multiple delivery routes.

The majority of foundational research originated from the University of Zagreb; independent replication is now expanding through institutions including Case Western Reserve University School of Medicine (2025 systematic review) and the Medical University of Gdansk.

References

Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025. https://pubmed.ncbi.nlm.nih.gov/40756949/

McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025. https://pubmed.ncbi.nlm.nih.gov/40789979/

Gwyer D, et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. https://pubmed.ncbi.nlm.nih.gov/30915550/

Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. https://pubmed.ncbi.nlm.nih.gov/21030672/

Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. https://pubmed.ncbi.nlm.nih.gov/25415472/

Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95(3):323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/

Huang T, et al. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Des Devel Ther. 2015;9:2485-2499. https://pubmed.ncbi.nlm.nih.gov/25995620/

Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine. 2025;31(5):20-24. https://pubmed.ncbi.nlm.nih.gov/40131143/

Sikiric P, et al. Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Vascular recruitment and gastrointestinal tract healing. Curr Pharm Des. 2018;24(18):1990-2001. https://pubmed.ncbi.nlm.nih.gov/29879879/

Wang L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs. Front Pharmacol. 2022;13. https://pubmed.ncbi.nlm.nih.gov/36588717/

Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Alternative Therapies in Health and Medicine. 2024;30(10):12-17. https://pubmed.ncbi.nlm.nih.gov/39325560/